Nabriva Therapeutics PLC (NBRVF)

[realfast95]

Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bact...


Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain from April 21-24, 2018.

These data are part of a growing body of evidence supporting lefamulin's profile as a promising first-in-class pleuromutilin antibiotic treatment for key pathogens, including multidrug resistant strains, known to cause community-acquired bacterial pneumonia (CABP).

“CABP is associated with a substantial economic and humanistic burden with significant morbidity and mortality for patients. With inappropriate use of currently available treatments, antibacterial resistance continues to rise. It is imperative that new classes of antibiotics continue to be developed to provide physicians treatment options for patients with serious infections,” said Jennifer Schranz, M.D., chief medical officer of Nabriva Therapeutics. “Following the positive results from LEAP 1, lefamulin has shown to provide a complete spectrum of activity that covers the most common bacterial causes of CABP, including multidrug resistant strains and atypical pathogens. We look forward to reporting topline efficacy and safety data from our LEAP 2 oral CABP trial this spring.”